Alpha Tau Medical (DRTS) Cost of Revenue (2021 - 2026)

Alpha Tau Medical has disclosed Cost of Revenue across 6 years of filings, most recently posting $241000.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $241000.0, down 47.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 27.82% YoY), and the FY2025 annual result was $1.9 million, down 20.82% from the prior year.
• Cost of Revenue came in at $241000.0 for Q1 2026 at Alpha Tau Medical, down from $452000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $687000.0 in Q4 2024 to a low of $121000.0 in Q2 2022.
• The 5-year median for Cost of Revenue is $459000.0 (2025), against an average of $432235.3.
• Across the five-year window, Cost of Revenue soared 329.75% in 2023 and tumbled 47.49% in 2026, its largest moves.
• Alpha Tau Medical's Cost of Revenue stood at $397000.0 in 2022, then climbed by 13.85% to $452000.0 in 2023, then soared by 51.99% to $687000.0 in 2024, then plunged by 34.21% to $452000.0 in 2025, then tumbled by 46.68% to $241000.0 in 2026.
• The last three Cost of Revenue figures came in at $241000.0 (Q1 2026), $452000.0 (Q4 2025), and $490000.0 (Q3 2025), per Business Quant data.